252 studies found for:    MC1R
Show Display Options
Rank Status Study
1 Completed Strength Training Induced Alterations in Markers of Immune Function
Condition: Inflammation
Intervention: Behavioral: Strength Training
2 Completed Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine
Condition: Vulvar Disease
Intervention: Drug: topical lidocaine + oral desipramine, and/or placebo
3 Recruiting Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma
Condition: Melanoma
Intervention:
4 Completed
Has Results
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
5 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
6 Completed A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Interventions: Drug: OSI-906;   Other: Placebo
7 Not yet recruiting 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
Conditions: High Risk MC4R Genotype;   Low Risk MC4R Genotype;   One Week or Less Antipsychotic Lifetime Exposure
Interventions: Drug: Ziprasidone;   Drug: aripiprazole, quetiapine, or risperidone
8 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV/r + Truvada
9 Unknown  Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol
Condition: Subsyndromal Delirium
Interventions: Drug: Haloperidol decanoate;   Drug: Placebo
10 Active, not recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or cobicistat + atazanavir + FTC/TDF
11 Terminated
Has Results
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Coenzyme Q10 with vitamin E;   Drug: placebo with vitamin E
12 Recruiting Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo;   Drug: Fulvestrant;   Drug: BKM120
13 Active, not recruiting
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Placebo;   Drug: Exemestane
14 Unknown  Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF;   Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
15 Completed
Has Results
Long-Term, Open Label Atomoxetine Study
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: atomoxetine
16 Enrolling by invitation Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Viaskin Peanut 250 mcg
17 Active, not recruiting A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Condition: Psoriasis
Interventions: Drug: 80mg LY2439821 Dosing Regimen;   Drug: Placebo
18 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237;   Drug: Placebo
19 Active, not recruiting Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Placebo
20 Recruiting Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
Conditions: Severe Sepsis;   Coagulopathy
Interventions: Drug: ART-123;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years